The relatively new drug safety issue of vision loss linked to Rybelsus and Ozempic was the subject of a recent medical study that had this stated Objective, or purpose: “To investigate the association between semaglutide use and the risk of NAION among patients with diabetes.”
On March 27, 2025, the JAMA Ophthalmology medical journal published this report, “Semaglutide and Nonarteritic Anterior Ischemic Optic Neuropathy Risk Among Patients With Diabetes”, about that recent medical study. Of particular significance is that it presents new information about the time relationship between Rybelsus and Ozempic use dates by patients with type 2 diabetes and the diagnosis dates for their NAION. This can be found in the Results section of that March 2025 JAMA Ophthalmology article, at a part titled “Risk of NAION in Terms of Follow-Up Duration After Semaglutide Prescription”.
Given an apparent delay in the onset of vision loss linked to Rybelsus and Ozempic leading to a NAION diagnosis, it seems we may have a still-emerging drug injury lawsuit situation here. That is, the increasing use of Rybelsus and Ozempic in combination with this delay in vision loss leading to a NAION diagnosis means we might be just at the start of hearing from diabetes patients who have suffered this blinding eye-related side effect.
Drug injury lawsuits involving vision loss linked to Rybelsus and Ozempic filed for patients with a diagnosis of NAION (nonarteritic anterior ischemic optic neuropathy) would be against Novo Nordisk for its failure to warn about such vision loss. This is because the current drug labels for Rybelsus and Ozempic do not warn about any eye-related side effects, such as vision loss and blindness due to NAION.
We have been investigating possible drug injury lawsuits for patients who developed vision loss linked to Rybelsus and Ozempic, two of three semaglutide-containing drugs from Novo Nordisk. Their other semaglutide drug is Wegovy, approved by the FDA as a treatment for adult obesity and used for weight loss.
Let us know if we can assist you or someone else with a Rybelsus, Oxempic, or Wegovy drug injury case concerning nonarteritic anterior ischemic optic neuropathy (NAION) leading to vision loss.
[View article at original source]Ozempic / Rybelsus / Wegovy
Free Case Evaluation
Strictly Confidential, No Obligation